ALLIGATOR BIOSCIENCE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.925 SEK | +1.09% |
|
-9.14% | +34.25% |
| Sales 2024 * | 266M 24.32M 1.95B | Sales 2025 * | 136M 12.4M 993M | Capitalization | 701M 64.09M 5.13B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | -72M -6.58M -527M | EV / Sales 2024 * | 1.52 x |
| Net cash position 2024 * | 298M 27.21M 2.18B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.17 x |
| P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-2.91
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alligator Bioscience AB
More press releases
| 1 day | +1.09% | ||
| 1 week | -9.14% | ||
| Current month | -6.94% | ||
| 1 month | -5.80% | ||
| 3 months | -23.81% | ||
| 6 months | +143.42% | ||
| Current year | +34.25% |
1 week
0.88
1.03
1 month
0.881.19
Current year
0.661.57
1 year
0.341.57
3 years
0.347.20
5 years
0.3426.85
10 years
0.3440.10
| Managers | Title | Age | Since |
|---|---|---|---|
Søren Bregenholt
CEO | Chief Executive Officer | 53 | 31/05/21 |
Marie Svensson
DFI | Director of Finance/CFO | 60 | 31/08/20 |
| Chief Tech/Sci/R&D Officer | 56 | 31/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graham Dixon
BRD | Director/Board Member | 63 | 08/05/19 |
| Chairman | 70 | 31/12/16 | |
Staffan Encrantz
BRD | Director/Board Member | 73 | 08/05/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.925 | +1.09% | 808,960 |
| 25/04/24 | 0.915 | -0.54% | 1,694,028 |
| 24/04/24 | 0.92 | -6.50% | 2,734,872 |
| 23/04/24 | 0.984 | -1.01% | 963,340 |
| 22/04/24 | 0.994 | -2.36% | 786,608 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Calendar
06/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.925
SEK
Average target price
2.3
SEK
Spread / Average Target
+148.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.25% | 63.95M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ATORX Stock
